ANNX
NASDAQ · Biotechnology
Annexon Inc
$4.90
-0.04 (-0.81%)
Open$5.10
Previous Close$4.94
Day High$5.21
Day Low$4.82
52W High$7.18
52W Low$1.85
Volume—
Avg Volume3.08M
Market Cap802.83M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+732.9% upside
Current
$4.90
$4.90
Target
$40.81
$40.81
$23.52
$40.81 avg
$51.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |
| Rev Growth | +7.5% | +20.0% | +0.3% |
| Debt/Equity | 0.32 | 0.38 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |